Premium
Effect of panobinostat (HDACi) alone and in combination with tamoxifen (PKCi) on glioblastoma cell line viability (1048.3)
Author(s) -
Trivedi Gaurang,
Benzeroual Kenza
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.1048.3
Subject(s) - panobinostat , viability assay , tamoxifen , cancer research , medicine , combination therapy , apoptosis , pharmacology , cancer , oncology , histone deacetylase , chemistry , histone , breast cancer , biochemistry , gene
Histone deacetylase inhibitors (HDACi) are a new generation of epigenetic modulators class of drugs but with low efficacy as cancer monotherapy, due to the upregulation of several tumor progressive genes. Combination of these drugs with various PKC inhibitors such as Tamoxifen showed increased efficiency for the treatment by inhibiting cell viability by nearly 50%. Panobinostat (LBH‐589) is a novel HDACi that induces apoptosis via multiple pathways in tumor cells. This study investigated the effect of Panobinostat alone and in combination with Tamoxifen on U‐87 Glioblastoma cell viability and subsequent morphological changes. Treatment with Panobinostat at IC50 showed 80% decrease in cell viability at 72 hours. Combination therapy of Panobinostat and Tamoxifen showed no significant decrease in cell viability as compared to a single therapy with Panobinostat. This was also observed morphologically. Our results report Panobinostat as a potential anticancer agent in glioblastoma. Further studies will investigate cancer progression in glioblastoma cell line.